These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. Yang L; Maxwell S; Leite MI; Waters P; Clover L; Fan X; Zhang D; Yang C; Beeson D; Vincent A J Neurol Sci; 2011 Feb; 301(1-2):71-6. PubMed ID: 21131008 [TBL] [Abstract][Full Text] [Related]
65. Diagnostic utility of cortactin antibodies in myasthenia gravis. Illa I; Cortés-Vicente E; Martínez MÁ; Gallardo E Ann N Y Acad Sci; 2018 Jan; 1412(1):90-94. PubMed ID: 29068555 [TBL] [Abstract][Full Text] [Related]
66. Are MuSK antibodies the primary cause of myasthenic symptoms? Selcen D; Fukuda T; Shen XM; Engel AG Neurology; 2004 Jun; 62(11):1945-50. PubMed ID: 15184594 [TBL] [Abstract][Full Text] [Related]
67. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Mori S; Shigemoto K Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506 [TBL] [Abstract][Full Text] [Related]
69. A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis. Ponseti JM; Caritg N; Gamez J; López-Cano M; Vilallonga R; Armengol M Expert Opin Biol Ther; 2009 Jan; 9(1):1-8. PubMed ID: 19063688 [TBL] [Abstract][Full Text] [Related]
70. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis. Hayashi A; Shiono H; Ohta M; Ohta K; Okumura M; Sawa Y J Neuroimmunol; 2007 Sep; 189(1-2):163-8. PubMed ID: 17706794 [TBL] [Abstract][Full Text] [Related]
72. High frequencies of circulating Tfh-Th17 cells in myasthenia gravis patients. Yang Y; Zhang M; Ye Y; Ma S; Fan L; Li Z Neurol Sci; 2017 Sep; 38(9):1599-1608. PubMed ID: 28578482 [TBL] [Abstract][Full Text] [Related]
73. Induction of myasthenia by immunization against muscle-specific kinase. Shigemoto K; Kubo S; Maruyama N; Hato N; Yamada H; Jie C; Kobayashi N; Mominoki K; Abe Y; Ueda N; Matsuda S J Clin Invest; 2006 Apr; 116(4):1016-24. PubMed ID: 16557298 [TBL] [Abstract][Full Text] [Related]
74. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451 [TBL] [Abstract][Full Text] [Related]
75. Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis. Boneva N; Frenkian-Cuvelier M; Bidault J; Brenner T; Berrih-Aknin S J Neuroimmunol; 2006 Aug; 177(1-2):119-31. PubMed ID: 16857268 [TBL] [Abstract][Full Text] [Related]
76. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Milani M; Ostlie N; Wang W; Conti-Fine BM Ann N Y Acad Sci; 2003 Sep; 998():284-307. PubMed ID: 14592887 [TBL] [Abstract][Full Text] [Related]